12.07.2015 Views

Volumen 68 • N.º 3 Julio-septiembre 2012 - Ministerio de Defensa

Volumen 68 • N.º 3 Julio-septiembre 2012 - Ministerio de Defensa

Volumen 68 • N.º 3 Julio-septiembre 2012 - Ministerio de Defensa

SHOW MORE
SHOW LESS
  • No tags were found...

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Evaluación positiva <strong>de</strong> medicamentos: 2.º trimestre <strong>2012</strong>17. Ostojic A, Urhovac R, Verstovsek S. Ruxolitinib for the treatment of myelofibrosis:its clinical potential. Therapeut Clin Riks Mang <strong>2012</strong>;8:95-103.18. Tefferi A, Pardanani A. Serious adverse events during ruxolitinibtreatment discontinuation in patients with myelofibrosis. Mayo Clin Proc2011; 86: 1188-91.19. Tefferi A, Litzow M, Pardanani A. Long-term outcome of treatmentwith ruxolitinib in myelofibrosis. NEJM 2011;365:1455-7.20. Jeppesen PB, Gilroy R, Pertkiewicz M et al. Randomised placebo-controlledtrial of tedugluti<strong>de</strong> in reducing parenteral nutrition and/or intravenousfluid requirements in patients with short bowel syndrome. Gut.2011; 60 (7): 902-14.21. Jeppesen PB. Tedugluti<strong>de</strong>, a novel glucagon-like pepti<strong>de</strong> 2 analog, in thetreatment of patients with short bowel syndrome. Therap Adv Gastroenterol<strong>2012</strong>; 5: 159-71.Sanid. mil. <strong>2012</strong>; <strong>68</strong> (3) 181

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!